FIRST TRACKS BIOTHERAPEUTICS INC (TRAX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$44.05+2.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge FIRST TRACKS BIOTHERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.835
Annual ending 2026-12-31
Revenue	—	75M
EPS	—	-4.116
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-3.682

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain a two-year cash runway and control operating losses during clinical development	First Tracks is advancing its drug ANB033 through early clinical trials with a two-year cash runway.	Intact	Cash runway falls below 12 months before new funding or revenue	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance ANB033 clinical trials to Phase 1b data and initiate Phase 2 trials in four indications	The firm is investing heavily now to reach Phase 2 trials in multiple indications.	Intact	Failure to initiate Phase 2 trials in at least two indications by 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 supplied quarters. The company's financials report operating expenses of $52.811 million in 2026-Q1 and $34.937 million in 2026-Q2, while no revenue is reported. Phase 1b trials are ongoing and Cohort 1 enrollment is complete, indicating clinical execution; financial results do not provide a revenue measure of progress. Delivery assessment Oct 24, 2026
Complete separation from AnaptysBio and establish independent operations	The company completed its spin-off and is building operational independence.	Intact	Failure to maintain independent operations or loss of key agreements by 2026-Q3	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.68

$-2.99 → $-3.68 · observed estimates

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-08-13	$-2.99	Unavailable	6 / 0
2026-08-14	$-2.99	Unavailable	6 / 0
2026-08-15	$-2.99	Unavailable	6 / 0
2026-08-16	$-2.99	Unavailable	6 / 0
2026-08-17	$-2.99	Unavailable	6 / 0
2026-08-18	$-2.99	Unavailable	6 / 0
2026-08-19	$-2.99	Unavailable	6 / 0
2026-08-20	$-3.23	Unavailable	6 / 0
2026-08-21	$-3.23	Unavailable	6 / 0
2026-08-22	$-3.23	Unavailable	6 / 0
2026-08-23	$-3.84	Unavailable	6 / 0
2026-08-24	$-3.84	Unavailable	6 / 0
2026-08-25	$-3.66	Unavailable	6 / 0
2026-08-26	$-3.66	Unavailable	6 / 0
2026-08-27	$-3.66	Unavailable	6 / 0
2026-08-28	$-3.66	Unavailable	6 / 0
2026-08-29	$-3.66	Unavailable	6 / 0
2026-08-30	$-3.66	Unavailable	6 / 0
2026-08-31	$-3.66	Unavailable	6 / 0
2026-09-01	$-3.66	Unavailable	6 / 0
2026-09-02	$-3.66	Unavailable	6 / 0
2026-09-03	$-3.66	Unavailable	6 / 0
2026-09-04	$-3.75	Unavailable	6 / 0
2026-09-05	$-3.75	Unavailable	6 / 0
2026-09-06	$-3.75	Unavailable	6 / 0
2026-09-07	$-3.75	Unavailable	6 / 0
2026-09-08	$-3.75	Unavailable	6 / 0
2026-09-09	$-3.75	Unavailable	6 / 0
2026-09-10	$-3.75	Unavailable	6 / 0
2026-09-11	$-3.75	Unavailable	6 / 0
2026-09-12	$-3.75	Unavailable	6 / 0
2026-09-13	$-3.75	Unavailable	6 / 0
2026-09-14	$-3.75	Unavailable	6 / 0
2026-09-15	$-3.75	Unavailable	6 / 0
2026-09-16	$-3.75	Unavailable	6 / 0
2026-09-17	$-3.78	Unavailable	6 / 0
2026-09-18	$-3.78	Unavailable	6 / 0
2026-09-19	$-3.78	Unavailable	6 / 0
2026-09-20	$-3.78	Unavailable	7 / 0
2026-09-21	$-3.78	Unavailable	7 / 0
2026-09-22	$-3.78	Unavailable	7 / 0
2026-09-23	$-3.78	Unavailable	7 / 0
2026-09-24	$-3.78	Unavailable	7 / 0
2026-09-25	$-3.78	Unavailable	7 / 0
2026-09-26	$-3.78	Unavailable	7 / 0
2026-09-27	$-3.78	Unavailable	7 / 0
2026-09-28	$-3.78	Unavailable	7 / 0
2026-09-29	$-3.72	Unavailable	7 / 0
2026-09-30	$-3.72	Unavailable	7 / 0
2026-10-01	$-3.72	Unavailable	7 / 0
2026-10-02	$-3.64	Unavailable	7 / 0
2026-10-03	$-3.64	Unavailable	7 / 0
2026-10-04	$-3.64	Unavailable	7 / 0
2026-10-05	$-3.64	Unavailable	7 / 0
2026-10-06	$-3.64	Unavailable	7 / 0
2026-10-07	$-3.64	Unavailable	7 / 0
2026-10-08	$-3.64	Unavailable	7 / 0
2026-10-09	$-3.64	Unavailable	7 / 0
2026-10-10	$-3.64	Unavailable	7 / 0
2026-10-11	$-3.64	Unavailable	7 / 0
2026-10-12	$-3.64	Unavailable	7 / 0
2026-10-13	$-3.64	Unavailable	7 / 0
2026-10-14	$-3.64	Unavailable	7 / 0
2026-10-15	$-3.64	Unavailable	7 / 0
2026-10-16	$-3.64	Unavailable	7 / 0
2026-10-17	$-3.64	Unavailable	7 / 0
2026-10-18	$-3.68	Unavailable	7 / 0
2026-10-19	$-3.68	Unavailable	7 / 0
2026-10-20	$-3.68	Unavailable	7 / 0
2026-10-21	$-3.68	Unavailable	7 / 0
2026-10-22	$-3.68	Unavailable	7 / 0
2026-10-23	$-3.68	Unavailable	7 / 0
2026-10-24	$-3.68	Unavailable	7 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	9	0	0
2026-09-01	12	0	0
2026-10-01	12	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Evercore ISIOct 13 · prior Sep 18

$65.00 → $70.00+7.7%

Canaccord GenuityOct 13 · prior Sep 30

$50.00 → $60.00+20.0%

Wells FargoOct 12 · prior Oct 9

$62.00 → $70.00+12.9%

$0$38.50$77.00

3 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain a two-year cash runway and control operating losses during clinical developmentDirect metric needs a verified mapping
Advance ANB033 clinical trials to Phase 1b data and initiate Phase 2 trials in four indicationsDirect metric needs a verified mapping
Complete separation from AnaptysBio and establish independent operationsDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.6%Typical daily move · historical

Downside history

-36.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

FIRST TRACKS BIOTHERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology company, not an established earnings compounder. The current thesis state is insufficient because there is not enough recent financial performance history, and confidence in the overall evidence is low.

What's priced into FIRST TRACKS BIOTHERAPEUTICS INC

The evidence snapshot gives no valuation level or specific market expectations, so whether TRAX is cheap or expensive versus peers cannot be assessed. No fragility gates fired, but that does not establish what the market already assumes.

What the fundamentals likely do

Near term, the elevated risk of an earnings miss is notable, and a guidance cut on the next call would be a meaningful negative. Over the multi-year view, ANB033 trial progress is the main visible sign of execution: Cohort 1 enrollment is complete and Phase 1b trials are ongoing, while the supplied results show operating expenses and no reported revenue. Cash and investments were reported at $168.0 million at June 30, 2026, and management reiterated runway into Q2 2028, though the reported cash measures declined and are not directly comparable.

What FIRST TRACKS BIOTHERAPEUTICS INC hinges on

The multi-year thesis hinges on continued clinical progress across ANB033 indications and the broader immunology pipeline, alongside enough funding to support development. Near term, a guidance cut or further weakening in jobs data could weigh on the setup; continued strength from healthcare bellwethers could support sector momentum, but the evidence does not show TRAX-specific earnings traction.